Sigachi Industries Share Analysis: FY26 Earnings and Outlook

Sigachi Industries Ltd.: overview

Sigachi Industries: Recovery, Expansion & Margin Rebuild Underway

Sigachi Industries (Market Cap: INR 822 Cr) one of India’s leading manufacturers of Microcrystalline Cellulose (MCC), appears to be entering a gradual recovery phase after navigating a challenging FY26 impacted by the Hyderabad facility disruption. While the temporary shutdown of the 6,000 MTPA Hyderabad plant impacted volumes, margins and exports during the year, Q4FY26 reflected early signs of operational normalization, improving utilization and margin recovery across the remaining facilities.

Q4FY26 Update: Early Signs of Stabilization & Margin Recovery

Post-incident, the company had undertaken extensive safety audits, customer audits and operational restructuring, which had temporarily elevated costs and suppressed utilization. Q4FY26 marked an important inflection point for Sigachi Industries Ltd. Revenue for the quarter stood at INR 122 Cr. More importantly, EBITDA improved sharply to INR 16 Cr with EBITDA margins recovering to 12.6%, compared to just 5% in Q3FY26.

The recovery in margins was primarily driven by better operational efficiencies at Dahej and Jhagadia plants with gradual normalization of utilization levels & improving contribution from higher-margin API and O&M businesses.

The Core Business Remains Strong

Despite temporary operational challenges, Sigachi’s core MCC business remains structurally strong. MCC contributes nearly 70% of the company’s total revenues, with Sigachi maintaining a strong presence across both domestic and international markets, exporting to over 60 countries globally. The company currently operates an MCC manufacturing capacity of 18,000 MTPA.

Capacity Expansion to Drive the Next Leg of Growth

To strengthen its leadership position, Sigachi Industries is undertaking a 12,000 MTPA MCC expansion project at its Dahej facility, which will increase the company’s total MCC capacity from 18,000 MTPA to 30,000 MTPA. At full capacity utilization, the new facility has the potential to generate incremental revenues of nearly INR 200–220 Cr annually. The MCC business generated ~INR 290 Cr revenue in FY26 at ~80% utilization levels. The Dahej expansion is expected to start contributing meaningfully from the end of FY27, positioning the company for a stronger growth trajectory over the long term.

CCS: A High-Margin Opportunity

Beyond MCC, Sigachi is also entering the specialty excipients segment through Croscarmellose Sodium (CCS). CCS commands significantly higher realizations than MCC and is expected to generate EBITDA margins exceeding 20%, making it a potentially meaningful contributor to future profitability. Expects commercialisation of the CCS facility in Q1 FY28.

API Business Emerging as Major Growth Driver:

Sigachi has been strategically expanding beyond its core excipients business into Active Pharmaceutical Ingredients (APIs), enabling the company to participate in a larger portion of the pharmaceutical value chain. The entry into APIs was strengthened through the acquisition of Trimax Biosciences, while the company has further enhanced its capabilities with a dedicated API R&D Centre in Hyderabad.

Sigachi has significantly increased the contribution of its API business to overall revenues. In Q4FY26, the API segment contributed 14% of total revenue, compared to just 2% in Q4FY25, reflecting strong scale-up and improved traction across key products. The company has guided for API revenues to increase from nearly INR 60 Cr in FY26 to over INR 100 Cr in FY27. Additionally, Sigachi’s cystic fibrosis API portfolio presents a potentially meaningful long-term opportunity, with management indicating sizeable revenue potential post-commercialization.

Sigachi’s Operations & Management (O&M) business continues to remain a steady. O&M business continues to provide a steady and highly profitable earnings stream contributing ~12% of revenue, the segment delivers EBITDA margins of around 21–22%.

Guidance & Outlook

Management has provided a strong FY27 outlook, guiding for revenues of INR 650–675 Cr, implying a robust growth of nearly 35% YoY, along with EBITDA margins expected to improve towards 18–20%. The company expects H2FY27 to be materially stronger than H1FY27, driven by better capacity utilization, operating leverage benefits, and a meaningful contribution from recent expansion initiatives. In all, Sigachi appears well-positioned for a gradual recovery in margins and stronger earnings growth over the medium term. Currently, the company is trading at 25 P/E of FY26.